4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
MABWELL-B (2493) operates in the Biotechnology industry and is headquartered in Shanghai, China with about 1,325 employees. Its market capitalization is roughly CNY 10 billion. In the fiscal year ended 2025-12-31, 2493 reported CNY 662M in revenue and (CNY 969M) in net income.
Mabwell (Shanghai) Bioscience Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacture, and commercialization of biological products for oncology, immunology, bone disorders, ophthalmology, hematology, and infectious diseases in China and internationally.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | CNY 662M | CNY 200M | CNY 128M | CNY 28M | — |
| Gross Profit | CNY 598M | CNY 171M | CNY 126M | CNY 28M | — |
| Operating Income (EBIT) | (CNY 851M) | (CNY 995M) | (CNY 1.1B) | (CNY 991M) | — |
| Net Income | (CNY 969M) | (CNY 1.0B) | (CNY 1.1B) | (CNY 955M) | — |
CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|
| Total Revenue | CNY 128M | CNY 97M | CNY 56M | CNY 45M | CNY 59M |
| Gross Profit | CNY 97M | CNY 71M | CNY 45M | CNY 35M | CNY 40M |
| Operating Income (EBIT) | (CNY 198M) | (CNY 339M) | (CNY 240M) | (CNY 269M) | (CNY 335M) |
| Net Income | (CNY 242M) | (CNY 372M) | (CNY 260M) | (CNY 292M) | (CNY 350M) |
CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Dividends Paid | (CNY 78M) | (CNY 66M) | (CNY 34M) | (CNY 13M) |
CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-03-31 | 2025-12-31 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|
| Dividends Paid | (CNY 24M) | (CNY 20M) | (CNY 18M) | (CNY 23M) | (CNY 21M) |
CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | CNY 4.6B | CNY 4.3B | CNY 4.5B | CNY 4.6B | — |
| Total Liabilities | CNY 4.0B | CNY 2.7B | CNY 1.9B | CNY 1.1B | — |
CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 2493 viewer.
About TickerBase · Data methodology & sources · Privacy · Terms